{"id":10197,"date":"2026-05-22T16:00:00","date_gmt":"2026-05-22T14:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=4672e1665b9c72d2281f808b5b60952f"},"modified":"2026-05-22T16:00:00","modified_gmt":"2026-05-22T14:00:00","slug":"saga-diagnostics-to-present-data-on-ultrasensitive-pathlight-mrd-test-in-breast-colon-and-rectal-cancers-at-asco-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=10197","title":{"rendered":"SAGA Diagnostics to Present Data on Ultrasensitive Pathlight\u2122 MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026"},"content":{"rendered":"

MORRISVILLE, N.C.--(BUSINESS WIRE)--#ASCO2026<\/a>--SAGA Diagnostics<\/a>, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29 to June 2 in Chicago.<\/p><\/a><\/a>

\nKey poster presentations highlight the expanding body of evidence supporting Pathlight\u2122, SAGA\u2019s tumor-informed structural variant (SV)-based circulating tumor DNA (ctDNA) platform, across both metastatic and localized settings. Retrospective analysis of PADA-1 samples will explore ctDNA kinetics during first-line therapy in metastatic breast cancer, while the real-world CITCCA cohort will evaluate Pathlight in colon and rectal cancer, through assessment of ctDNA clearance, recurrence risk, and outcomes in localized disease.<\/p>

\n\u201cAs MRD testing becomes increasingly important in oncology, clinicians need assays capable of detecting patient-specific molecular residual disease at the lowest possible levels across a broad range of clinical settings,\u201d said Wendy Levin, MD, MS, Chief Clinical Officer at SAGA Diagnostics. \u201cThe data being presented at ASCO 2026 further highlight the potential of Pathlight\u2019s ultrasensitive tumor-informed ctDNA approach to support treatment monitoring, recurrence assessment, and longitudinal disease surveillance across both metastatic and localized cancers.\u201d<\/p>

\nKey SAGA Diagnostics Presentations During ASCO 2026:<\/b><\/p>\n\n\n\n\n

\nAbstract Title<\/b><\/p><\/td>

\nPresentation Details<\/b><\/p><\/td><\/tr>\n

\nctDNA kinetics throughout first-line AI and palbociclib using a tumor-informed structural variant-based ctDNA assay: retrospective analysis of PADA-1 samples<\/p>

\n\u00a0<\/p><\/td>

\nAbstract: 3050<\/p>

\nPoster: 187<\/p>

\nDate: May 30, 2026<\/p>

\nTime: 1:30 - 4:30 PM<\/p>

\nSpeaker: Luc Cabel, Institut Curie<\/p>

\n\u00a0<\/p><\/td><\/tr>\n

\nCirculating Tumor DNA Clearance of Adjuvant Chemotherapy in Localized Colorectal Cancer Using an Ultrasensitive Structural Variant\u2013Based Assay<\/p>

\n\u00a0<\/p><\/td>

\nAbstract: 3625<\/p>

\nPoster: 392<\/p>

\nDate: May 30, 2026<\/p>

\nTime: 9:00 - 12:00 PM<\/p>

\nSpeaker: Cecilia Merk, MD, Karolinska Institutet<\/p>

\n\u00a0<\/p><\/td><\/tr>\n

\nLocalized Rectal Cancer Outcomes Predicted by ctDNA Analysis Using a Novel Ultrasensitive Structural Variant (SV)-based Method<\/p>

\n\u00a0<\/p><\/td>

\nAbstract: 3619<\/p>

\nPoster: 386<\/p>

\nDate: May 30, 2026<\/p>

\nTime: 9:00 - 12:00 PM<\/p>

\nSpeaker: Cecilia Merk, MD, Karolinska Institutet<\/p><\/td><\/tr>\n<\/table>

\nThe full abstracts for SAGA Diagnostics at ASCO 2026 can be found here<\/a>.<\/p>

\nAbout SAGA Diagnostics<\/b><\/p>

\nSAGA Diagnostics\u00ae is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight\u2122, the company\u2019s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with early-stage breast cancer. SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities, to support early through late-stage cancer development programs across a range of cancer types. SAGA\u2019s headquarters and CLIA-certified laboratory are located in the heart of the life science ecosystem in Research Triangle Park, North Carolina. SAGA Diagnostics combines world-class genomic expertise with a leadership team deeply experienced in MRD, all aligned in the mission to intercept cancer at its earliest stages when it is most treatable.<\/p>

\nFor more information, visit www.sagadiagnostics.com<\/a><\/p> Contacts<\/b>

\nMedia Contact:<\/b>media@sagadiagnostics.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

MORRISVILLE, N.C.–(BUSINESS WIRE)–#ASCO2026–SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three abstract…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10197","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10197"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10197\/revisions"}],"predecessor-version":[{"id":10198,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10197\/revisions\/10198"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}